{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T22:30:21Z","timestamp":1766788221961,"version":"3.41.0"},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["1165936","1165936","1165936"],"award-info":[{"award-number":["1165936","1165936","1165936"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Inform Decis Mak"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Simulation modelling can assist with health care decision making. To inform the development and improvement of skin cancer focussed microsimulation models, we conducted a systematic review and narrative synthesis of published skin cancer models to assess the structure, parameterisation, and assumptions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The electronic databases OVIDMedline including Embase and the Cost-Effectiveness Analysis (CEA) Registry were searched up to 7 May 2025. Studies that included microsimulation of individuals who developed or had skin cancer were eligible for inclusion. No restrictions on publication date or language were applied. The outcomes of interest were the purpose of the models, characteristics of the models and applicability for modelling skin cancer screening.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Twenty-two models were identified from the systematic review. Nineteen papers modelled melanoma, and two papers modelled keratinocyte or non-melanoma skin cancer, and one paper modelled both melanoma and keratinocyte cancer. The models were developed to assess treatment strategies (<jats:italic>n<\/jats:italic>\u2009=\u200910), skin cancer screening programs (<jats:italic>n<\/jats:italic>\u2009=\u20097), diagnostic techniques (<jats:italic>n<\/jats:italic>\u2009=\u20093), post-diagnosis surveillance (<jats:italic>n<\/jats:italic>\u2009=\u20093), preventative interventions (<jats:italic>n<\/jats:italic>\u2009=\u20091) and time to treatment (<jats:italic>n<\/jats:italic>\u2009=\u20091), with three models reporting dual aims. There was substantial variation in the simulation of the natural history of melanoma between models, with more recent models having separate natural history and clinical modules. The quality was assessed using the Quality Assessment Reporting for Microsimulation Models (QARMM) checklist and the majority of models were assessed to be of moderate quality. Limitations from these models included assuming an average tumour behaviour and constant melanoma development and progression over time. Data availability was also noted as a limitation for some models.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Most microsimulation models related to skin cancer have focused on late-stage treatment strategies. Tumour characteristics, apart from stage at diagnosis, were not accounted for in most models.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PROSPERO registration number <\/jats:title>\n            <jats:p>CRD42024504250.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12911-025-03074-9","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T10:12:39Z","timestamp":1751364759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A systematic review of microsimulation models for skin cancer"],"prefix":"10.1186","volume":"25","author":[{"given":"Caroline G.","family":"Watts","sequence":"first","affiliation":[]},{"given":"Kirstie G.","family":"McLoughlin","sequence":"additional","affiliation":[]},{"given":"Stephen","family":"Wade","sequence":"additional","affiliation":[]},{"given":"Amelia K.","family":"Smit","sequence":"additional","affiliation":[]},{"given":"H. Peter","family":"Soyer","sequence":"additional","affiliation":[]},{"given":"Pablo","family":"Fernandez-Pe\u00f1as","sequence":"additional","affiliation":[]},{"given":"David C.","family":"Whiteman","sequence":"additional","affiliation":[]},{"given":"Pascale","family":"Guitera","sequence":"additional","affiliation":[]},{"given":"Gillian","family":"Reyes-Marcelino","sequence":"additional","affiliation":[]},{"given":"Karen","family":"Canfell","sequence":"additional","affiliation":[]},{"given":"Anne E.","family":"Cust","sequence":"additional","affiliation":[]},{"given":"Michael","family":"Caruana","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"issue":"3","key":"3074_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"Cancer J Clin"},{"key":"3074_CR2","doi-asserted-by":"crossref","unstructured":"Olsen CM, Pandeya N, Green AC, Ragaini BS, Venn AJ, Whiteman DC. Keratinocyte cancer incidence in australia: a review of population-based incidence trends and estimates of lifetime risk. Public Health Res Pract. 2022;32(1).","DOI":"10.17061\/phrp3212203"},{"issue":"1","key":"3074_CR3","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jaad.2005.08.072","volume":"54","author":"JF Aitken","year":"2006","unstructured":"Aitken JF, Janda M, Elwood M, Youl PH, Ring IT, Lowe JB. Clinical outcomes from skin screening clinics within a community-based melanoma screening program. J Am Acad Dermatol. 2006;54(1):105\u201314.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"3074_CR4","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/jso.20079","volume":"86","author":"U Leiter","year":"2004","unstructured":"Leiter U, Meier F, Schittek B, Garbe C. The natural course of cutaneous melanoma. J Surg Oncol. 2004;86(4):172\u20138.","journal-title":"J Surg Oncol"},{"issue":"1","key":"3074_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejca.2004.10.016","volume":"41","author":"S Gandini","year":"2005","unstructured":"Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P, et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2005;41(1):45\u201360.","journal-title":"Eur J Cancer"},{"issue":"14","key":"3074_CR6","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1016\/j.ejca.2005.03.034","volume":"41","author":"S Gandini","year":"2005","unstructured":"Gandini S, Sera F, Cattaruzza MS, Pasquini P, Zanetti R, Masini C, et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer. 2005;41(14):2040\u201359.","journal-title":"Eur J Cancer"},{"key":"3074_CR7","doi-asserted-by":"publisher","first-page":"4678362","DOI":"10.1155\/2018\/4678362","volume":"2018","author":"MIM Choudhury","year":"2018","unstructured":"Choudhury MIM, Shabnam N, Ahsan T, Ahsan SMA, Kabir MS, Khan RM, et al. Cutaneous malignancy due to arsenicosis in bangladesh: 12-Year study in tertiary level hospital. Biomed Res Int. 2018;2018:4678362.","journal-title":"Biomed Res Int"},{"key":"3074_CR8","doi-asserted-by":"crossref","unstructured":"Walker H, Maitland C, Tabbakh T, Preston P, Wakefield M, Sinclair C. Forty years of slip! Slop! Slap! A call to action on skin cancer prevention for Australia. Public Health Res Pract. 2022;32(1).","DOI":"10.17061\/phrp31452117"},{"issue":"3","key":"3074_CR9","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/cncr.29755","volume":"122","author":"A Stang","year":"2016","unstructured":"Stang A, J\u00f6ckel KH. Does skin cancer screening save lives? A detailed analysis of mortality time trends in Schleswig-Holstein and Germany. Cancer. 2016;122(3):432\u20137.","journal-title":"Cancer"},{"issue":"15","key":"3074_CR10","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1001\/jama.2023.3262","volume":"329","author":"NB Henrikson","year":"2023","unstructured":"Henrikson NB, Ivlev I, Blasi PR, Nguyen MB, Senger CA, Perdue LA, et al. Skin Cancer screening: updated evidence report and systematic review for the US preventive services task force. JAMA. 2023;329(15):1296\u2013307.","journal-title":"JAMA"},{"issue":"12","key":"3074_CR11","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1001\/jamadermatol.2021.3884","volume":"157","author":"CG Watts","year":"2021","unstructured":"Watts CG, McLoughlin K, Goumas C, van Kemenade CH, Aitken JF, Soyer HP, et al. Association between melanoma detected during routine skin checks and mortality. JAMA Dermatol. 2021;157(12):1425\u201336.","journal-title":"JAMA Dermatol"},{"issue":"2","key":"3074_CR12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/ijc.24747","volume":"126","author":"JF Aitken","year":"2010","unstructured":"Aitken JF, Elwood M, Baade PD, Youl P, English D. Clinical whole-body skin examination reduces the incidence of Thick melanomas. Int J Cancer. 2010;126(2):450\u20138.","journal-title":"Int J Cancer"},{"issue":"9","key":"3074_CR13","doi-asserted-by":"publisher","first-page":"e868","DOI":"10.1097\/GOX.0000000000000826","volume":"4","author":"JT Chen","year":"2016","unstructured":"Chen JT, Kempton SJ, Rao VK. The economics of skin cancer: an analysis of medicare payment data. Plast Reconstr Surg \u2013 Global Open. 2016;4(9):e868.","journal-title":"Plast Reconstr Surg \u2013 Global Open"},{"key":"3074_CR14","doi-asserted-by":"crossref","unstructured":"Gordon LG, Leung W, Johns R, McNoe B, Lindsay D, Merollini KMD et al. Estimated healthcare costs of melanoma and keratinocyte skin cancers in Australia and Aotearoa new Zealand in 2021. Int J Environ Res Public Health. 2022;19(6).","DOI":"10.3390\/ijerph19063178"},{"issue":"2","key":"3074_CR15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/1753-6405.12972","volume":"44","author":"M Janda","year":"2020","unstructured":"Janda M, Cust AE, Neale RE, Aitken JF, Baade PD, Green AC, et al. Early detection of melanoma: a consensus report from the Australian skin and skin Cancer research centre melanoma screening summit. Aust N Z J Public Health. 2020;44(2):111\u20135.","journal-title":"Aust N Z J Public Health"},{"issue":"1","key":"3074_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.34196\/ijm.00064","volume":"5","author":"E Zucchelli","year":"2012","unstructured":"Zucchelli E, Jones AM, Rice N. The evaluation of health policies through dynamic microsimulation methods. IJM. 2012;5(1):2\u201320.","journal-title":"IJM"},{"issue":"1","key":"3074_CR17","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1186\/s12911-021-01713-5","volume":"21","author":"A Bespalov","year":"2021","unstructured":"Bespalov A, Barchuk A, Auvinen A, Nevalainen J. Cancer screening simulation models: a state of the Art review. BMC Med Inf Decis Mak. 2021;21(1):359.","journal-title":"BMC Med Inf Decis Mak"},{"issue":"8","key":"3074_CR18","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1002\/ijc.23633","volume":"123","author":"MA Smith","year":"2008","unstructured":"Smith MA, Canfell K, Brotherton JM, Lew JB, Barnabas RV. The predicted impact of vaccination on human papillomavirus infections in Australia. Int J Cancer. 2008;123(8):1854\u201363.","journal-title":"Int J Cancer"},{"issue":"48","key":"3074_CR19","doi-asserted-by":"publisher","first-page":"9112","DOI":"10.1016\/j.vaccine.2011.02.091","volume":"29","author":"MA Smith","year":"2011","unstructured":"Smith MA, Lew JB, Walker RJ, Brotherton JM, Nickson C, Canfell K. The predicted impact of HPV vaccination on male infections and male HPV-related cancers in Australia. Vaccine. 2011;29(48):9112\u201322.","journal-title":"Vaccine"},{"issue":"5","key":"3074_CR20","doi-asserted-by":"publisher","first-page":"e0151619","DOI":"10.1371\/journal.pone.0151619","volume":"11","author":"JB Lew","year":"2016","unstructured":"Lew JB, Simms K, Smith M, Lewis H, Neal H, Canfell K. Effectiveness modelling and economic evaluation of primary HPV screening for cervical Cancer prevention in new Zealand. PLoS ONE. 2016;11(5):e0151619.","journal-title":"PLoS ONE"},{"key":"3074_CR21","doi-asserted-by":"crossref","unstructured":"Lew JB, Feletto E, Wade S, Caruana M, Kang YJ, Nickson C et al. Benefits, harms and cost-effectiveness of cancer screening in australia: an overview of modelling estimates. Public Health Res Pract. 2019;29(2).","DOI":"10.17061\/phrp2921913"},{"issue":"12","key":"3074_CR22","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1158\/1055-9965.EPI-18-0128","volume":"27","author":"J-B Lew","year":"2018","unstructured":"Lew J-B, St John DJB, Macrae FA, Emery JD, Ee HC, Jenkins MA, et al. Benefits, harms, and Cost-Effectiveness of potential age extensions to the National bowel Cancer screening program in Australia. Cancer Epidemiol Biomarkers Prev. 2018;27(12):1450\u201361.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"8","key":"3074_CR23","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.jtho.2018.04.006","volume":"13","author":"S Wade","year":"2018","unstructured":"Wade S, Weber M, Caruana M, Kang Y-J, Marshall H, Manser R, et al. Estimating the Cost-Effectiveness of lung Cancer screening with Low-Dose computed tomography for High-Risk smokers in Australia. J Thorac Oncol. 2018;13(8):1094\u2013105.","journal-title":"J Thorac Oncol"},{"issue":"10224","key":"3074_CR24","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/S0140-6736(20)30157-4","volume":"395","author":"K Canfell","year":"2020","unstructured":"Canfell K, Kim JJ, Brisson M, Keane A, Simms KT, Caruana M, et al. Mortality impact of achieving WHO cervical cancer elimination targets: a comparative modelling analysis in 78 low-income and lower-middle-income countries. Lancet. 2020;395(10224):591\u2013603.","journal-title":"Lancet"},{"issue":"3","key":"3074_CR25","doi-asserted-by":"publisher","first-page":"e1003534","DOI":"10.1371\/journal.pmed.1003534","volume":"18","author":"JJ Kim","year":"2021","unstructured":"Kim JJ, Simms KT, Killen J, Smith MA, Burger EA, Sy S, et al. Human papillomavirus vaccination for adults aged 30 to 45 years in the united states: A cost-effectiveness analysis. PLoS Med. 2021;18(3):e1003534.","journal-title":"PLoS Med"},{"key":"3074_CR26","unstructured":"The Center for the Evaluation of Value. and Risk in Health,Institute for Clinical Research and Health Policy Studies [Internet]. 2018."},{"key":"3074_CR27","unstructured":"Covidence systematic [internet]eview software [Internet]. Veritas Health Innovation."},{"key":"3074_CR28","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"1","key":"3074_CR29","doi-asserted-by":"publisher","first-page":"198","DOI":"10.34196\/ijm.00178","volume":"11","author":"H Sutherland","year":"2018","unstructured":"Sutherland H. Quality assessment of microsimulation models. The case of EUROMOD. Int J Microsimulation. 2018;11(1):198\u2013223.","journal-title":"Int J Microsimulation"},{"issue":"2","key":"3074_CR30","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.jval.2023.10.015","volume":"27","author":"C de Oliveira","year":"2024","unstructured":"de Oliveira C, Matias MA, Jacobs R. Microsimulation models on mental health: A critical review of the literature. Value Health. 2024;27(2):226\u201346.","journal-title":"Value Health"},{"issue":"13","key":"3074_CR31","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1002\/cncr.33499","volume":"127","author":"A Eskander","year":"2021","unstructured":"Eskander A, Marqueen KE, Edwards HA, Joshua AM, Petrella TM, de Almeida JR, et al. To ban or not to ban tanning bed use for minors: A cost-effectiveness analysis from multiple US perspectives for invasive melanoma. Cancer. 2021;127(13):2333\u201341.","journal-title":"Cancer"},{"issue":"12","key":"3074_CR32","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1158\/1055-9965.EPI-20-0881","volume":"29","author":"KC Gogebakan","year":"2020","unstructured":"Gogebakan KC, Berry EG, Geller AC, Sonmez K, Leachman SA, Etzioni R. Strategizing screening for melanoma in an era of novel treatments: A Model-Based approach. Cancer Epidemiol Biomarkers Prev. 2020;29(12):2599\u2013607.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"3074_CR33","doi-asserted-by":"publisher","first-page":"e220269","DOI":"10.1001\/jamanetworkopen.2022.0269","volume":"5","author":"J Gomez Rossi","year":"2022","unstructured":"Gomez Rossi J, Rojas-Perilla N, Krois J, Schwendicke F. Cost-effectiveness of artificial intelligence as a Decision-Support system applied to the detection and grading of melanoma, dental caries, and diabetic retinopathy. JAMA Netw Open. 2022;5(3):e220269.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"3074_CR34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12913-023-09058-7","volume":"23","author":"SN Li","year":"2023","unstructured":"Li SN, Wan X, Peng LB, Li YM, Li JH. Cost-effectiveness of immune checkpoint Inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma. BMC Health Serv Res. 2023;23(1):49.","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"3074_CR35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1001\/archderm.143.1.21","volume":"143","author":"E Losina","year":"2007","unstructured":"Losina E, Walensky RP, Geller A, Beddingfield FC 3rd, Wolf LL, Gilchrest BA, et al. Visual screening for malignant melanoma: a cost-effectiveness analysis. Arch Dermatol. 2007;143(1):21\u20138.","journal-title":"Arch Dermatol"},{"issue":"13","key":"3074_CR36","doi-asserted-by":"publisher","first-page":"9039","DOI":"10.1245\/s10434-021-10288-4","volume":"28","author":"SA Mojtahed","year":"2021","unstructured":"Mojtahed SA, Boyer NR, Rao SA, Gajewski TF, Tseng J, Turaga KK. Cost-Effectiveness analysis of adjuvant therapy for BRAF-Mutant resected stage III melanoma in medicare patients. Ann Surg Oncol. 2021;28(13):9039\u201347.","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"3074_CR37","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1111\/j.1524-4725.2009.01291.x","volume":"35","author":"AM Seidler","year":"2009","unstructured":"Seidler AM, Bramlette TB, Washington CV, Szeto H, Chen SC. Mohs versus traditional surgical excision for facial and auricular nonmelanoma skin cancer: an analysis of cost-effectiveness. Dermatol Surg. 2009;35(11):1776\u201387.","journal-title":"Dermatol Surg"},{"issue":"14","key":"3074_CR38","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.2217\/imt-2018-0085","volume":"10","author":"A Tarhini","year":"2018","unstructured":"Tarhini A, Benedict A, McDermott D, Rao S, Ambavane A, Gupte-Singh K, et al. Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis. Immunotherapy. 2018;10(14):1241\u201352.","journal-title":"Immunotherapy"},{"issue":"1","key":"3074_CR39","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1001\/jamadermatol.2018.3958","volume":"155","author":"AR Almutairi","year":"2019","unstructured":"Almutairi AR, Alkhatib NS, Oh M, Curiel-Lewandrowski C, Babiker HM, Cranmer LD, et al. Economic evaluation of talimogene Laherparepvec plus ipilimumab combination therapy vs ipilimumab monotherapy in patients with advanced unresectable melanoma. JAMA Dermatol. 2019;155(1):22\u20138.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"3074_CR40","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1586\/erp.13.22","volume":"13","author":"AR Kansal","year":"2013","unstructured":"Kansal AR, Shaul AJ, Stern S, Busam K, Doucet CA, Chalfin DB. Cost-effectiveness of a FISH assay for the diagnosis of melanoma in the USA. Expert Rev Pharmacoecon Outcomes Res. 2013;13(3):371\u201380.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"13","key":"3074_CR41","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1097\/01.MIB.0000435850.17263.13","volume":"19","author":"PN Okafor","year":"2013","unstructured":"Okafor PN, Stallwood CG, Nguyen L, Sahni D, Wasan SK, Farraye FA, et al. Cost-effectiveness of nonmelanoma skin cancer screening in crohn\u2019s disease patients. Inflamm Bowel Dis. 2013;19(13):2787\u201395.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"3074_CR42","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/j.1524-4733.2004.74005.x","volume":"7","author":"R Crott","year":"2004","unstructured":"Crott R, Ali F, Burdette-Radoux S. Cost-utility of adjuvant high-dose interferon alpha therapy in stage III cutaneous melanoma in Quebec. Value Health. 2004;7(4):423\u201332.","journal-title":"Value Health"},{"issue":"6","key":"3074_CR43","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1080\/13696998.2019.1569446","volume":"22","author":"EJ Gibson","year":"2019","unstructured":"Gibson EJ, Begum N, Koblbauer I, Dranitsaris G, Liew D, McEwan P, et al. Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma. J Med Econ. 2019;22(6):531\u201344.","journal-title":"J Med Econ"},{"issue":"1","key":"3074_CR44","doi-asserted-by":"publisher","first-page":"238146832110699","DOI":"10.1177\/23814683211069988","volume":"7","author":"V Kontogiannis","year":"2022","unstructured":"Kontogiannis V, Coughlan D, Javanbakht M, Kunonga P, Beyer F, Richmond C, et al. Optimal surveillance strategies for Early-Stage cutaneous melanoma post primary tumor excision: an economic evaluation. MDM Policy Pract. 2022;7(1):23814683211069988.","journal-title":"MDM Policy Pract"},{"issue":"12","key":"3074_CR45","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s40273-013-0094-x","volume":"31","author":"S Beale","year":"2013","unstructured":"Beale S, Dickson R, Bagust A, Blundell M, Dundar Y, Boland A, et al. Vemurafenib for the treatment of locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma: a NICE single technology appraisal. PharmacoEconomics. 2013;31(12):1121\u20139.","journal-title":"PharmacoEconomics"},{"issue":"1","key":"3074_CR46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s41669-018-0080-5","volume":"3","author":"D Lee","year":"2019","unstructured":"Lee D, Amadi A, Sabater J, Ellis J, Johnson H, Kotapati S, et al. Can we accurately predict cost effectiveness without access to overall survival data?? The case study of nivolumab in combination with ipilimumab for the treatment of patients with advanced melanoma in England. Pharmacoecon Open. 2019;3(1):43\u201354.","journal-title":"Pharmacoecon Open"},{"issue":"6","key":"3074_CR47","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.jval.2017.11.009","volume":"21","author":"ECF Wilson","year":"2018","unstructured":"Wilson ECF, Usher-Smith JA, Emery J, Corrie P, Walter FM. A modeling study of the Cost-Effectiveness of a Risk-Stratified surveillance program for melanoma in the united Kingdom. Value Health. 2018;21(6):658\u201368.","journal-title":"Value Health"},{"issue":"2","key":"3074_CR48","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2340\/00015555-2222","volume":"96","author":"M Claeson","year":"2016","unstructured":"Claeson M, Hallberg S, Holmstrom P, Wennberg AM, Gonzalez H, Paoli J. Modelling the future: system dynamics in the cutaneous malignant melanoma care pathway. Acta Derm Venereol. 2016;96(2):181\u20135.","journal-title":"Acta Derm Venereol"},{"key":"3074_CR49","first-page":"115","volume":"15","author":"E van der Meijde","year":"2016","unstructured":"van der Meijde E, van den Eertwegh AJ, Linn SC, Meijer GA, Fijneman RJ, Coupe VM. The melanoma MAICare framework: A microsimulation model for the assessment of individualized Cancer care. Cancer Inf. 2016;15:115\u201327.","journal-title":"Cancer Inf"},{"issue":"2","key":"3074_CR50","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1177\/0272989X14543106","volume":"35","author":"N Eisemann","year":"2015","unstructured":"Eisemann N, Waldmann A, Garbe C, Katalinic A. Development of a microsimulation of melanoma mortality for evaluating the effectiveness of population-based skin cancer screening. Med Decis Mak. 2015;35(2):243\u201354.","journal-title":"Med Decis Mak"},{"issue":"1","key":"3074_CR51","first-page":"19","volume":"23","author":"H Baltus","year":"2025","unstructured":"Baltus H, H\u00fcbner J, Garbe C, Hagenstr\u00f6m K, Rohr M, Hischke S, et al. Evaluation of skin cancer screening in Germany - a microsimulation. J Dtsch Dermatol Ges. 2025;23(1):19\u201327.","journal-title":"J Dtsch Dermatol Ges"},{"key":"3074_CR52","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1200\/CCI.20.00124","volume":"5","author":"S Walpole","year":"2021","unstructured":"Walpole S, Hayward NK, Pritchard AL, Johansson PA. Microsimulation model for evaluating the Cost-Effectiveness of surveillance in BAP1 pathogenic variant carriers. JCO Clin Cancer Inf. 2021;5:143\u201354.","journal-title":"JCO Clin Cancer Inf"},{"issue":"4","key":"3074_CR53","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/j.1365-2133.2010.10185.x","volume":"164","author":"JH Lee","year":"2011","unstructured":"Lee JH, Choi JW, Kim YS. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol. 2011;164(4):776\u201384.","journal-title":"Br J Dermatol"},{"issue":"Suppl 3","key":"3074_CR54","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/S0959-8049(98)00002-1","volume":"34","author":"BE Hillner","year":"1998","unstructured":"Hillner BE. Cost-effectiveness assessment of interferon alfa-2b as adjuvant therapy of high-risk resected cutaneous melanoma. Eur J Cancer. 1998;34(Suppl 3):S18\u201321.","journal-title":"Eur J Cancer"},{"issue":"12","key":"3074_CR55","doi-asserted-by":"publisher","first-page":"e0145524","DOI":"10.1371\/journal.pone.0145524","volume":"10","author":"J Larkin","year":"2015","unstructured":"Larkin J, Hatswell AJ, Nathan P, Lebmeier M, Lee D. The predicted impact of ipilimumab usage on survival in previously treated advanced or metastatic melanoma in the UK. PLoS ONE. 2015;10(12):e0145524.","journal-title":"PLoS ONE"},{"issue":"4","key":"3074_CR56","doi-asserted-by":"publisher","first-page":"236","DOI":"10.7326\/M15-0754","volume":"164","author":"J Birnbaum","year":"2016","unstructured":"Birnbaum J, Gadi VK, Markowitz E, Etzioni R. The effect of treatment advances on the mortality results of breast Cancer screening trials: A microsimulation model. Ann Intern Med. 2016;164(4):236\u201343.","journal-title":"Ann Intern Med"},{"issue":"3","key":"3074_CR57","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1111\/j.1365-2036.2010.04356.x","volume":"32","author":"DC Malone","year":"2010","unstructured":"Malone DC, Waters HC, Van Den Bos J, Popp J, Draaghtel K, Rahman MI. A claims-based Markov model for crohn\u2019s disease. Aliment Pharmacol Ther. 2010;32(3):448\u201358.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"3074_CR58","doi-asserted-by":"publisher","first-page":"e2020033","DOI":"10.5826\/dpc.1003a33","volume":"10","author":"AM Forsea","year":"2020","unstructured":"Forsea AM. Melanoma epidemiology and early detection in europe: diversity and disparities. Dermatol Pract Concept. 2020;10(3):e2020033.","journal-title":"Dermatol Pract Concept"},{"issue":"1","key":"3074_CR59","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/JCO.2016.68.4308","volume":"35","author":"CG Watts","year":"2017","unstructured":"Watts CG, Cust AE, Menzies SW, Mann GJ, Morton RL. Cost-Effectiveness of skin surveillance through a specialized clinic for patients at high risk of melanoma. J Clin Oncol. 2017;35(1):63\u201371.","journal-title":"J Clin Oncol"},{"key":"3074_CR60","doi-asserted-by":"publisher","first-page":"101874","DOI":"10.1016\/j.canep.2020.101874","volume":"70","author":"G Reyes-Marcelino","year":"2021","unstructured":"Reyes-Marcelino G, Tabbakh T, Espinoza D, Sinclair C, Kang YJ, McLoughlin K, et al. Prevalence of skin examination behaviours among Australians over time. Cancer Epidemiol. 2021;70:101874.","journal-title":"Cancer Epidemiol"},{"key":"3074_CR61","unstructured":"Australian Institute of Health and Welfare. Rural and remote health.: AIHW. 2023 [updated 11 September 2023. Available from: https:\/\/www.aihw.gov.au\/reports\/rural-remote-australians\/rural-and-remote-health"},{"issue":"3","key":"3074_CR62","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.ejor.2011.10.041","volume":"219","author":"SC Brailsford","year":"2012","unstructured":"Brailsford SC, Harper PR, Sykes J. Incorporating human behaviour in simulation models of screening for breast cancer. Eur J Oper Res. 2012;219(3):491\u2013507.","journal-title":"Eur J Oper Res"},{"issue":"2","key":"3074_CR63","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1524-4733.2004.72326.x","volume":"7","author":"JH Wu","year":"2004","unstructured":"Wu JH, Fung MC, Chan W, Lairson DR. Cost-effectiveness analysis of interventions to enhance mammography compliance using computer modeling (CAN*TROL). Value Health. 2004;7(2):175\u201385.","journal-title":"Value Health"},{"issue":"1","key":"3074_CR64","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1056\/NEJMsb2019760","volume":"384","author":"HG Welch","year":"2021","unstructured":"Welch HG, Mazer BL, Adamson AS. The rapid rise in cutaneous melanoma diagnoses. N Engl J Med. 2021;384(1):72\u20139.","journal-title":"N Engl J Med"},{"issue":"7","key":"3074_CR65","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1016\/j.jid.2021.12.003","volume":"142","author":"NR Kurtansky","year":"2022","unstructured":"Kurtansky NR, Dusza SW, Halpern AC, Hartman RI, Geller AC, Marghoob AA, et al. An epidemiologic analysis of melanoma overdiagnosis in the united states, 1975\u20132017. J Invest Dermatol. 2022;142(7):1804\u2013e116.","journal-title":"J Invest Dermatol"},{"issue":"10","key":"3074_CR66","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1093\/jnci\/djac138","volume":"114","author":"CM Olsen","year":"2022","unstructured":"Olsen CM, Pandeya N, Rosenberg PS, Whiteman DC. Incidence of in situ vs invasive melanoma: testing the obligate precursor hypothesis. J Natl Cancer Inst. 2022;114(10):1364\u201370.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"3074_CR67","doi-asserted-by":"publisher","first-page":"e116","DOI":"10.1002\/ski2.116","volume":"3","author":"TT Win Myint","year":"2023","unstructured":"Win Myint TT, Selak V, Elwood M. The risk of subsequent invasive melanoma after a primary in situ or invasive melanoma in a high incidence country (New Zealand). Skin Health Dis. 2023;3(2):e116.","journal-title":"Skin Health Dis"},{"issue":"7","key":"3074_CR68","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1001\/jamadermatol.2023.1485","volume":"159","author":"AE Cust","year":"2023","unstructured":"Cust AE, Scolyer RA. Melanoma in Situ-Getting the diagnosis and prognosis right. JAMA Dermatol. 2023;159(7):699\u2013701.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"3074_CR69","first-page":"147","volume":"56","author":"J Brodersen","year":"2017","unstructured":"Brodersen J. Overdiagnosis: an unrecognised and growing worldwide problem in healthcare. Zdr Varst. 2017;56(3):147\u20139.","journal-title":"Zdr Varst"},{"issue":"4","key":"3074_CR70","doi-asserted-by":"publisher","first-page":"163","DOI":"10.5694\/mja2.50455","volume":"212","author":"PP Glasziou","year":"2020","unstructured":"Glasziou PP, Jones MA, Pathirana T, Barratt AL, Bell KJ. Estimating the magnitude of cancer overdiagnosis in Australia. Med J Aust. 2020;212(4):163\u20138.","journal-title":"Med J Aust"},{"issue":"2","key":"3074_CR71","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1093\/bjd\/ljad275","volume":"190","author":"J Smith","year":"2023","unstructured":"Smith J, Cust AE, Lo SN. Risk factors for subsequent primary melanoma in patients with previous melanoma: a systematic review and meta-analysis. Br J Dermatol. 2023;190(2):174\u201383.","journal-title":"Br J Dermatol"},{"key":"3074_CR72","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.pmedr.2018.04.011","volume":"10","author":"PM Risica","year":"2018","unstructured":"Risica PM, Matthews NH, Dionne L, Mello J, Ferris LK, Saul M, et al. Psychosocial consequences of skin cancer screening. Prev Med Rep. 2018;10:310\u20136.","journal-title":"Prev Med Rep"},{"issue":"4","key":"3074_CR73","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1159\/000530225","volume":"239","author":"Y Liu","year":"2023","unstructured":"Liu Y, Primiero CA, Kulkarni V, Soyer HP, Betz-Stablein B. Artificial intelligence for the classification of pigmented skin lesions in populations with skin of color: A systematic review. Dermatology. 2023;239(4):499\u2013513.","journal-title":"Dermatology"},{"key":"3074_CR74","doi-asserted-by":"publisher","first-page":"102263","DOI":"10.1016\/j.canep.2022.102263","volume":"81","author":"K Blazek","year":"2022","unstructured":"Blazek K, Furestad E, Ryan D, Damian D, Fernandez-Penas P, Tong S. The impact of skin cancer prevention efforts in new South wales, australia: generational trends in melanoma incidence and mortality. Cancer Epidemiol. 2022;81:102263.","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"3074_CR75","first-page":"1","volume":"18","author":"N Rasheed","year":"2024","unstructured":"Rasheed N. Melanoma awareness programs and their impact on the life of Australian queenslanders: A concise analysis. Int J Health Sci (Qassim). 2024;18(1):1\u20133.","journal-title":"Int J Health Sci (Qassim)"},{"issue":"6","key":"3074_CR76","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.jid.2016.01.035","volume":"136","author":"DC Whiteman","year":"2016","unstructured":"Whiteman DC, Green AC, Olsen CM. The growing burden of invasive melanoma: projections of incidence rates and numbers of new cases in six susceptible populations through 2031. J Invest Dermatol. 2016;136(6):1161\u201371.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"3074_CR77","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1002\/ijc.27616","volume":"132","author":"F Erdmann","year":"2013","unstructured":"Erdmann F, Lortet-Tieulent J, Schuz J, Zeeb H, Greinert R, Breitbart EW, et al. International trends in the incidence of malignant melanoma 1953\u20132008\u2013are recent generations at higher or lower risk? Int J Cancer. 2013;132(2):385\u2013400.","journal-title":"Int J Cancer"},{"issue":"5","key":"3074_CR78","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","volume":"158","author":"M Arnold","year":"2022","unstructured":"Arnold M, Singh D, Laversanne M, Vignat J, Vaccarella S, Meheus F, et al. Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol. 2022;158(5):495\u2013503.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"3074_CR79","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1177\/0272989X11408730","volume":"31","author":"KM Kuntz","year":"2011","unstructured":"Kuntz KM, Lansdorp-Vogelaar I, Rutter CM, Knudsen AB, van Ballegooijen M, Savarino JE, et al. A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression. Med Decis Mak. 2011;31(4):530\u20139.","journal-title":"Med Decis Mak"},{"issue":"6","key":"3074_CR80","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.jval.2017.10.009","volume":"21","author":"ECF Wilson","year":"2018","unstructured":"Wilson ECF, Usher-Smith JA, Emery J, Corrie PG, Walter FM. Expert elicitation of multinomial probabilities for Decision-Analytic modeling: an application to rates of disease progression in undiagnosed and untreated melanoma. Value Health. 2018;21(6):669\u201376.","journal-title":"Value Health"},{"issue":"2","key":"3074_CR81","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/jnci\/djy086","volume":"111","author":"M Lattanzi","year":"2019","unstructured":"Lattanzi M, Lee Y, Simpson D, Moran U, Darvishian F, Kim RH, et al. Primary melanoma histologic subtype: impact on survival and response to therapy. J Natl Cancer Inst. 2019;111(2):180\u20138.","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"3074_CR82","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1093\/jnci\/djz048","volume":"111","author":"TE Burbidge","year":"2019","unstructured":"Burbidge TE, Bastian BC, Guo D, Li H, Morris DG, Monzon JG, et al. Association of indoor tanning exposure with age at melanoma diagnosis and BRAF V600E mutations. J Natl Cancer Inst. 2019;111(11):1228\u201331.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"3074_CR83","first-page":"147","volume":"185","author":"R Ghiasvand","year":"2017","unstructured":"Ghiasvand R, Rueegg CS, Weiderpass E, Green AC, Lund E, Veierod MB. Indoor tanning and melanoma risk: Long-Term evidence from a prospective Population-Based cohort study. Am J Epidemiol. 2017;185(3):147\u201356.","journal-title":"Am J Epidemiol"},{"issue":"6","key":"3074_CR84","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","volume":"15","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, Kuntz KM, Force I-SMGRPT. Modeling good research practices\u2013overview: a report of the ISPOR-SMDM modeling good research practices task Force\u20131. Value Health. 2012;15(6):796\u2013803.","journal-title":"Value Health"},{"issue":"38","key":"3074_CR85","first-page":"629","volume":"112","author":"A Katalinic","year":"2015","unstructured":"Katalinic A, Eisemann N, Waldmann A. Skin Cancer screening in germany. Documenting melanoma incidence and mortality from 2008 to 2013. Dtsch Arztebl Int. 2015;112(38):629\u201334.","journal-title":"Dtsch Arztebl Int"},{"issue":"9","key":"3074_CR86","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1002\/ijc.25540","volume":"128","author":"PH Youl","year":"2011","unstructured":"Youl PH, Baade PD, Parekh S, English D, Elwood M, Aitken JF. Association between melanoma thickness, clinical skin examination and socioeconomic status: results of a large population-based study. Int J Cancer. 2011;128(9):2158\u201365.","journal-title":"Int J Cancer"},{"issue":"4","key":"3074_CR87","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.jaad.2012.09.047","volume":"68","author":"V Mar","year":"2013","unstructured":"Mar V, Roberts H, Wolfe R, English DR, Kelly JW. Nodular melanoma: a distinct clinical entity and the largest contributor to melanoma deaths in victoria, Australia. J Am Acad Dermatol. 2013;68(4):568\u201375.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"3074_CR88","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1001\/archderm.142.12.1551","volume":"142","author":"W Liu","year":"2006","unstructured":"Liu W, Dowling JP, Murray WK, McArthur GA, Thompson JF, Wolfe R, et al. Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol. 2006;142(12):1551\u20138.","journal-title":"Arch Dermatol"},{"issue":"2","key":"3074_CR89","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/CMR.0000000000000619","volume":"30","author":"SW Menzies","year":"2020","unstructured":"Menzies SW, Liyanarachchi S, Coates E, Smith A, Cooke-Yarborough C, Lo S, et al. Estimated risk of progression of Lentigo Maligna to Lentigo Maligna melanoma. Melanoma Res. 2020;30(2):193\u20137.","journal-title":"Melanoma Res"},{"key":"3074_CR90","unstructured":"8th ed Gershenwald_et_al 2017.pdf>."},{"issue":"5","key":"3074_CR91","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/bjd.18524","volume":"182","author":"AE Cust","year":"2020","unstructured":"Cust AE, Badcock C, Smith J, Thomas NE, Haydu LE, Armstrong BK, et al. A risk prediction model for the development of subsequent primary melanoma in a population-based cohort. Br J Dermatol. 2020;182(5):1148\u201357.","journal-title":"Br J Dermatol"},{"key":"3074_CR92","doi-asserted-by":"publisher","first-page":"637069","DOI":"10.3389\/fmed.2021.637069","volume":"8","author":"A Blundo","year":"2021","unstructured":"Blundo A, Cignoni A, Banfi T, Ciuti G. Comparative analysis of diagnostic techniques for melanoma detection: A systematic review of diagnostic test accuracy studies and Meta-Analysis. Front Med (Lausanne). 2021;8:637069.","journal-title":"Front Med (Lausanne)"},{"issue":"2","key":"3074_CR93","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/00008390-200304000-00011","volume":"13","author":"P Carli","year":"2003","unstructured":"Carli P, Mannone F, De Giorgi V, Nardini P, Chiarugi A, Giannotti B. The problem of false-positive diagnosis in melanoma screening: the impact of dermoscopy. Melanoma Res. 2003;13(2):179\u201382.","journal-title":"Melanoma Res"},{"key":"3074_CR94","unstructured":"-2017-AJCC Eighth Edition Cancer Staging Manual Cancer J Clin.pdf>."},{"issue":"36","key":"3074_CR95","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199\u2013206.","journal-title":"J Clin Oncol"}],"container-title":["BMC Medical Informatics and Decision Making"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-025-03074-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12911-025-03074-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12911-025-03074-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:03:06Z","timestamp":1751367786000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedinformdecismak.biomedcentral.com\/articles\/10.1186\/s12911-025-03074-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":95,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3074"],"URL":"https:\/\/doi.org\/10.1186\/s12911-025-03074-9","relation":{},"ISSN":["1472-6947"],"issn-type":[{"value":"1472-6947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"4 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HPS is a shareholder of MoleMap NZ Limited and e-derm consult GmbH and undertakes regular teledermatological reporting for both companies. HPS is a Medical Consultant for Canfield Scientific Inc and a Medical Advisor for First Derm. The other authors have no conflicts of interest to declare.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"222"}}